RxDoctor Payments DataLook up a doctor →

Weiwei Dai, DO

Neurology · Rio Rancho, NMNPI 1417248469

Payments from drug & device makers

$366,755in general payments, 2019–2025

Across 1,222 payments — averaging $300.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$208K
  • Lilly USA, LLC$39K
  • Pfizer$37K
  • Lundbeck LLC$27K
  • Biohaven Pharmaceuticals, Inc.$23K
  • Biohaven Pharmaceutical Holding Company Ltd.$14K
  • plus $19K from 40 others

What the payments were for

  • Consulting fees$13,1874%
  • Speaking & faculty fees$292,41480%
  • Grants$850%
  • Travel & lodging$28,5668%
  • Food & beverage$32,4409%
  • Education$630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$366,755 in reported general payments places this provider in the 95th percentile of 91 neurology providers in New Mexico.

See all neurology providers in New Mexico

Medicare billing

Part B allowed, 2024
$91,655
Medicare patients
306
Services billed
912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe204$186,557
UbrelvyUbrogepant94$170,557
Nurtec OdtRimegepant Sulfate50$150,724
Emgality PenGalcanezumab-Gnlm83$59,530
QuliptaAtogepant42$59,155
Teriflunomide27$48,323
BotoxOnabotulinumtoxina36$46,082
RexultiBrexpiprazole22$30,003
Ajovy AutoinjectorFremanezumab-Vfrm18$29,899
AptiomEslicarbazepine Acetate11$26,647
Sumatriptan Succinate458$18,497
Glatiramer Acetate12$16,654
Emgality SyringeGalcanezumab-Gnlm13$14,218
XcopriCenobamate12$13,858
Sumatriptan129$13,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$208,157$275,794172 claims
PfizerNurtec Odt, Dilantin$36,852$154,33663 claims
Otsuka America Pharmaceutical, Inc.Rexulti$314$30,00322 claims
Sunovion Pharmaceuticals Inc.Aptiom$112$26,64711 claims
SK Life Science, Inc.Xcopri$448$13,85812 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$144$5,65967 claims
Upsher-smith Laboratories LLCTopiramate$254$3,769255 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 91 neurology providers in New Mexico.

Other neurology in Rio Rancho

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →